Received Jun 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 324BY | — |
received the 1st dose on 2019. On may 3rd, 2025 the 2nd dose of Twinrix was administered.; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a patient who received HAB (Twinrix) (batch number 324BY, expiry date 28-SEP-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose in 2019). On 03-MAY-2025, the patient received the 2nd dose of Twinrix. On 03-MAY-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: received the 1st dose on 2019. On may 3rd, 2025 the 2nd dose of Twinrix was administered.). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-JUN-2025 The pharmacist reported that the patient had Twinrix received the 1st dose in 2019 and on 3rd May 2025 the 2nd dose of Twinrix was administered. The reporter asked how they treat that situation and did it count as the first or does the third dose would be in October 2025 and asked should they restart the series. The patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccination schedule; Sender's Comments: US2025072143:Case created for 2nd patient